I'm sure many long term holders of MSB had their confidence peaked by this announcement. Why was Fast Track designation announced? Did the prospect of success really deteriorate so badly after 45% readout? This announcement sticks out like a sore thumb.
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS, page-525
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.025(1.88%) |
Mkt cap ! $1.547B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.40 | $1.34 | $3.350M | 2.458M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 34808 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 4349 | 10 |
View Market Depth
| Last trade - 15.28pm 07/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |